• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Annexon Inc. (Amendment)

    2/14/24 12:43:14 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANNX alert in real time by email
    SC 13G/A 1 sc13ga_annexon.htm SC 13G/A

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

    Annexon, Inc.

    (Name of Issuer – as specified in its charter)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    03589W102

    (CUSIP Number)

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    þ       Rule 13d-1(b)

    ¨        Rule 13d-1(c)

    ¨        Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     
     

     

    1

    NAME OF REPORTING PERSON

    Eventide Asset Management, LLC

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    ¨ (a)

    ¨ (b)

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

    0

     

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

     

    12

    TYPE OF REPORTING PERSON

    IA

           

     

     
     

     

    1

    NAME OF REPORTING PERSON

    Finny Kuruvilla, M.D. Ph. D.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    ¨ (a)

    ¨ (b)

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

    0

     

    6

    SHARED VOTING POWER

    0

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

     

    12

    TYPE OF REPORTING PERSON

    IN;HC

           

     

     
     

     

    1

    NAME OF REPORTING PERSON

    Robin C. John

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    ¨ (a)

    ¨ (b)

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

    0

     

    6

    SHARED VOTING POWER

    0

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

     

    12

    TYPE OF REPORTING PERSON

    IN;HC

           

     

     
     

    Item 1. (a) Name of Issuer:

    Annexon, Inc. (the “Issuer”)

    (b) Address of Issuer’s Principal Executive Offices:

    1400 Sierra Point Parkway, Bldg C, Suite 200, Brisbane, California, 94005

    Item 2. (a) Name of Persons Filing:

    (i) Eventide Asset Management, LLC (“Eventide”)

    (ii) Finny Kuruvilla, M.D., Ph.D. (“Kuruvilla”)

    (iii) Robin C. John (“John”)

    (b). Address of Principal Business Office or, if none, Residence:

    Eventide, Kuruvilla and John:

    One International Place, Suite 4210

    Boston, Massachusetts 02110

    (c). Citizenship or Place of Organization:

    Eventide: Delaware

    Kuruvilla: United States

    John: United States

    (d). Title of Class of Securities:

    Common Stock, $0.001 par value

     

    (e). CUSIP Number:

    03589W102

    Item 3. If this statement is filed pursuant to sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

    (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

    (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

    (e) [x] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E);

    (f) [ ] An employee benefit plan or endowment fund in accordance with section 240.13d- 1(b)(1)(ii)(F);

    (g) [x] A parent holding company or control person in accordance with section 240.13d- 1(b)(1)(ii)(G);

    (h) [ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance

    Act (12 U.S.C. 1813);

    (i) [ ] A church plan that is excluded from the definition of an investment company under

     
     

            section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j) [ ] A non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J);

    (k) [ ] A group, in accordance with section 240.13d-1(b)(1) (ii)(K).

    If filing as a non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

    Item 4. Ownership:

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

    (a). Amount beneficially owned:

    (i) Eventide: 0

    (ii) Kuruvilla: 0

    (iii) John: 0

    (b). Percent of class:

    (i) Eventide: 0.0%

    (ii) Kuruvilla: 0.0%

    (iii) John: 0.0%

    (c). Number of shares as to which the person has:

    (i)        Sole power to vote or to direct the vote:

    (1) Eventide: 0

    (2) Kuruvilla: 0

    (3) John: 0

    (ii)        Shared power to vote or to direct the vote:

     

    (1) Eventide: 0

    (2) Kuruvilla: 0

    (3) John: 0

    (iii) Sole power to dispose or to direct the disposition of:

    (1) Eventide: 0

    (2) Kuruvilla: 0

    (3) John: 0

    (iv) Shared power to dispose or to direct the disposition of:

    (1) Eventide: 0

    (2) Kuruvilla: 0

    (3) John: 0

     
     

    Item 5. Ownership of Five Percent or Less of a Class:

    This statement is being filed to report the fact that as of the date hereof Eventide Asset Management, LLC has ceased to be the beneficial owner of more than five percent of the Issuer’s outstanding Common Stock.

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:

    Not Applicable

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company:

    Not Applicable

    Item 8. Identification and Classification of Members of the Group:

    Not Applicable

    Item 9. Notice of Dissolution of Group:

    Not Applicable

    Item 10. Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

     
     

    SIGNATURES

    The undersigned certify, after reasonable inquiry and to the best knowledge and belief of the undersigned, that the information set forth in this Statement is true, complete and correct. The undersigned agree to the filing of this single Statement on Schedule 13G.

     

    Eventide Asset Management, LLC

    Date: February 14, 2024

    By: /s/ Peter J. Luiso

    Name: Peter J. Luiso

    Title: General Counsel

     

    Finny Kuruvilla, M.D., Ph. D.

    Date: February 14, 2024

    By: /s/ Finny Kuruvilla, M.D., Ph. D.

    Name: Finny Kuruvilla, M.D., Ph. D.

    Robin C. John

    Date: February 14, 2024

    By: /s/ Robin C. John

    Name: Robin C. John

     
     

    EXHIBIT 1

    WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto is filed on behalf of each of them;

    NOW, THEREFORE, the parties hereto agree as follows:

    Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph. D. and Robin C. John do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file a Statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Statement on Schedule 13G shall be filed on behalf of each of them.

     

    Eventide Asset Management, LLC

    Date: February 14, 2024

    By: /s/ Peter J. Luiso

    Name: Peter J. Luiso

    Title: General Counsel

     

    Finny Kuruvilla, M.D., Ph. D.

    Date: February 14, 2024

    By: /s/ Finny Kuruvilla, M.D., Ph. D.

    Name: Finny Kuruvilla, M.D., Ph. D.

    Robin C. John

    Date: February 14, 2024

    By: /s/ Robin C. John

    Name: Robin C. John

    Get the next $ANNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANNX

    DatePrice TargetRatingAnalyst
    12/23/2025$16.00Buy
    Chardan Capital Markets
    3/1/2024$11.00Neutral → Overweight
    JP Morgan
    12/21/2023$4.00 → $6.00Neutral → Buy
    BofA Securities
    10/30/2023$11.00Overweight
    Wells Fargo
    5/26/2023$8.00 → $3.00Buy → Neutral
    BofA Securities
    5/25/2023$19.00 → $9.00Overweight → Neutral
    JP Morgan
    9/16/2022$12.00Buy
    Jefferies
    9/9/2022$15.00Buy
    BTIG Research
    More analyst ratings

    $ANNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets initiated coverage on Annexon with a new price target

    Chardan Capital Markets initiated coverage of Annexon with a rating of Buy and set a new price target of $16.00

    12/23/25 8:41:58 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon upgraded by JP Morgan with a new price target

    JP Morgan upgraded Annexon from Neutral to Overweight and set a new price target of $11.00

    3/1/24 7:27:25 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon upgraded by BofA Securities with a new price target

    BofA Securities upgraded Annexon from Neutral to Buy and set a new price target of $6.00 from $4.00 previously

    12/21/23 6:41:39 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

    BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on January 9, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate, the new non-executive employees received options to purchase 155,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal

    1/16/26 5:05:12 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026

    Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026 Vonaprument Pivotal Phase 3 Topline Data for Dry AMD with Geographic Atrophy (GA) on Track for Second Half of 2026 Evaluating Unprecedented Effect on Vision Protection Proof-of-Concept Data for ANX1502, the First Oral C1 Inhibitor for Autoimmune Disease, Expected in 2026 Strong Financial Position Funds Operations into Late 2027 Well Past Anticipated Key Milestones BRISBANE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of tar

    1/12/26 7:00:00 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome

    Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from FORWARD Trial Planned in 2026 BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tanruprubart for the treatment of Guillain-Barré syndrome (GBS). "Annexon's first regulatory submission marks a defining milestone for patients a

    1/8/26 8:00:00 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Annexon Inc.

    SCHEDULE 13G/A - Annexon, Inc. (0001528115) (Subject)

    2/5/26 1:16:32 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Annexon, Inc. (0001528115) (Filer)

    1/14/26 4:05:15 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Annexon Inc.

    8-K - Annexon, Inc. (0001528115) (Filer)

    1/12/26 7:05:13 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Carson William H. bought $20,657 worth of shares (4,115 units at $5.02), increasing direct ownership by 8% to 54,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    1/2/26 4:30:06 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Carson William H. bought $18,394 worth of shares (4,115 units at $4.47), increasing direct ownership by 9% to 50,290 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    12/3/25 4:30:14 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Choi Jung bought $138,270 worth of shares (33,000 units at $4.19) (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    12/3/25 4:30:20 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Carson William H. bought $20,657 worth of shares (4,115 units at $5.02), increasing direct ownership by 8% to 54,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    1/2/26 4:30:06 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Carson William H. bought $18,394 worth of shares (4,115 units at $4.47), increasing direct ownership by 9% to 50,290 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    12/3/25 4:30:14 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Choi Jung bought $138,270 worth of shares (33,000 units at $4.19) (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    12/3/25 4:30:20 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Annexon Inc.

    SC 13G/A - Annexon, Inc. (0001528115) (Subject)

    11/14/24 7:21:59 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Annexon Inc.

    SC 13G/A - Annexon, Inc. (0001528115) (Subject)

    11/14/24 6:46:41 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Annexon Inc.

    SC 13G/A - Annexon, Inc. (0001528115) (Subject)

    11/14/24 5:30:27 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    Leadership Updates

    Live Leadership Updates

    View All

    Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

    Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability Package to Support a BLA Accelerated Completion of Enrollment for Global Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry AMD with GA; Selected for EMA PRIME Product Development Candidate Pilot; Topline ARCHER II Data Expected in Second Half of 2026 ANX1502 First-in-Kind Oral C1s Inhibitor Exposure Exceeded Target Concentration in Fasted Patients; Evaluation in Relation to Food Intake Ongoing in Proof-of-Concept CAD Study, Update Expected by Year-end 2025 $227 Million i

    8/14/25 4:05:00 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

    Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors ANX007 is the Only Investigational Program Shown to Significantly Preserve Vision and Central Retinal Photoreceptors Critical for Visual Acuity Enrollment of Phase 3 ARCHER II Trial Expected to be Completed in Q3 2025, with Topline Data Expected in Second Half of 2026 BRISBANE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-medi

    6/18/25 4:05:00 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors

    Aviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment car

    4/9/25 7:00:00 AM ET
    $ANNX
    $LUMO
    $GRAY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    Financials

    Live finance-specific insights

    View All

    Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

    Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in Guillain-Barré Syndrome (GBS) and Geographic Atrophy (GA) Current Tanruprubart GBS Dossier On Track for MAA Filing in January 2026; Potential to Be the First Approved Targeted and Fast-Acting Therapy for the Treatment of GBS; Continued FDA Discussions Regarding Generalizability Package in Support of BLA Filing Topline ARCHER II Pivotal Data for Vonaprument in Dry AMD with GA on Track for Second Half of 2026; Potential to Be the First Approved Vision Sparing Therapy for the Treatment of Eight Million GA Patients Worldwide ANX1502 Cold Agglutinin Disease (CAD) Proof of Concept Study Ongoing with Expected 2026

    11/10/25 4:05:00 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

    Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS) Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across Multiple Measurements Conference Call and Webcast Today at 8:30 a.m. ET BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the

    12/16/24 7:30:00 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome

    Single Infusion of ANX005 30 mg/kg Met Primary Endpoint, Delivering a Highly Statistically Significant and Clinically Meaningful 2.4-fold Improvement in GBS-DS vs. Placebo at Week 8, p=0.0058 ANX005 Demonstrated Early and Sustained Improvements in Key Secondary Endpoints Including Muscle Strength, Nerve Damage and Ventilation ANX005 Displayed Rapid Target Engagement and was Generally Well-Tolerated Across Doses Real-World Evidence (RWE) Comparability Data Expected in First Half 2025 Conference call and webcast today at 8:30 a.m. ET BRISBANE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage platform of novel ther

    6/4/24 7:00:00 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care